DK3513192T3 - Celledødsbiomarkør - Google Patents
Celledødsbiomarkør Download PDFInfo
- Publication number
- DK3513192T3 DK3513192T3 DK17771553.9T DK17771553T DK3513192T3 DK 3513192 T3 DK3513192 T3 DK 3513192T3 DK 17771553 T DK17771553 T DK 17771553T DK 3513192 T3 DK3513192 T3 DK 3513192T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell death
- biomarker
- death biomarker
- cell
- death
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1615842.0A GB201615842D0 (en) | 2016-09-16 | 2016-09-16 | Cell death biomarker |
PCT/GB2017/052733 WO2018051110A1 (en) | 2016-09-16 | 2017-09-15 | Cell death biomarker |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3513192T3 true DK3513192T3 (da) | 2021-03-29 |
Family
ID=57288813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17771553.9T DK3513192T3 (da) | 2016-09-16 | 2017-09-15 | Celledødsbiomarkør |
Country Status (8)
Country | Link |
---|---|
US (2) | US11789012B2 (da) |
EP (1) | EP3513192B1 (da) |
JP (1) | JP7211936B2 (da) |
AU (1) | AU2017327994B2 (da) |
DK (1) | DK3513192T3 (da) |
ES (1) | ES2863274T3 (da) |
GB (1) | GB201615842D0 (da) |
WO (1) | WO2018051110A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
CN112961864A (zh) * | 2021-02-26 | 2021-06-15 | 广州市妇女儿童医疗中心 | 突变的asxl3基因及应用 |
CN114478797B (zh) * | 2021-11-24 | 2023-10-27 | 中山大学附属第五医院 | 一种靶向ddx24蛋白的水解靶向嵌合体及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070037165A1 (en) * | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US20020169123A1 (en) * | 2001-02-27 | 2002-11-14 | The Trustees Of The University Of Pennsylvania | Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells |
ZA200900043B (en) * | 2006-06-20 | 2010-03-31 | Genentech Inc | Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components |
GB2484003B (en) * | 2010-09-23 | 2013-04-24 | Univ Washington | Compositions and methods for detecting uveal melanoma cancer metastasis risk |
US20140011696A1 (en) * | 2011-02-16 | 2014-01-09 | Thomas Wiesner | Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia |
WO2014156527A1 (ja) * | 2013-03-28 | 2014-10-02 | 国立大学法人東北大学 | 食道癌の発症リスクを判定する方法及びキット |
CN105705504A (zh) * | 2013-10-10 | 2016-06-22 | 密歇根大学董事会 | 去泛素化酶抑制剂及其使用方法 |
US20160101071A1 (en) * | 2014-04-28 | 2016-04-14 | Wisconsin Alumni Research Foundation | Combination cancer treatment |
CA2948883A1 (en) * | 2014-06-02 | 2015-12-10 | Pharmakea, Inc. | Deubiquitinase inhibitors |
CA2952285A1 (en) * | 2014-06-19 | 2015-12-23 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
-
2016
- 2016-09-16 GB GBGB1615842.0A patent/GB201615842D0/en not_active Ceased
-
2017
- 2017-09-15 ES ES17771553T patent/ES2863274T3/es active Active
- 2017-09-15 JP JP2019514263A patent/JP7211936B2/ja active Active
- 2017-09-15 EP EP17771553.9A patent/EP3513192B1/en active Active
- 2017-09-15 AU AU2017327994A patent/AU2017327994B2/en active Active
- 2017-09-15 DK DK17771553.9T patent/DK3513192T3/da active
- 2017-09-15 US US16/333,590 patent/US11789012B2/en active Active
- 2017-09-15 WO PCT/GB2017/052733 patent/WO2018051110A1/en unknown
-
2023
- 2023-04-12 US US18/299,415 patent/US20240118266A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190257818A1 (en) | 2019-08-22 |
EP3513192A1 (en) | 2019-07-24 |
JP2020500502A (ja) | 2020-01-16 |
ES2863274T3 (es) | 2021-10-11 |
AU2017327994A1 (en) | 2019-04-04 |
WO2018051110A1 (en) | 2018-03-22 |
US20240118266A1 (en) | 2024-04-11 |
EP3513192B1 (en) | 2020-12-23 |
GB201615842D0 (en) | 2016-11-02 |
AU2017327994B2 (en) | 2023-09-14 |
US11789012B2 (en) | 2023-10-17 |
JP7211936B2 (ja) | 2023-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3303568T3 (da) | Celle | |
DK3627029T3 (da) | Manipulationssikret låg | |
DK3538864T3 (da) | Mikrotom | |
DK3237442T3 (da) | Celle | |
DK3448882T3 (da) | Anti-kk-lc-1-t-cellereceptorer | |
DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
MA43957A (fr) | Biomarqueurs de copanlisib | |
MA43958A (fr) | Biomarqueurs copanlisib | |
DK3427323T3 (da) | Brændselscelle | |
DK3365107T3 (da) | Cellekultur | |
DK3513192T3 (da) | Celledødsbiomarkør | |
DK3145536T3 (da) | Modificeret tyrosinammoniaklyase | |
FI11623U1 (fi) | Kuormaa kantava rakenne | |
DK3253769T3 (da) | Hidtil ukendte polymorfer | |
FR3022880B1 (fr) | Eolienne flottante | |
FI20145330A (fi) | Immunomääritys | |
FR3056990B1 (fr) | Marqueurs cellulaires | |
DE112014007261A5 (de) | Messanordnung | |
FI20145828A (fi) | Näytteenotin | |
UA34266S (uk) | Акумуляторна батарея | |
UA34454S (uk) | Рубанок | |
UA34654S (uk) | Блокнот | |
UA35581S (uk) | Акумуляторна батарея | |
UA35580S (uk) | Акумуляторна батарея | |
UA35362S (uk) | Акумуляторна батарея |